Duopan Litong Pian (多潘立酮片)多潘立酮片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 辰欣药业股份有限公司Chinese legal name: 辰欣药业股份有限公司
主要成分Active Ingredients
- 多潘立酮Duopan Litong
药物知识说明
多潘立酮是一种在国家药监局注册认定的药品。该药品含有多潘立酮-12f030aa等成分。
该药品关联的活性成分包括：多潘立酮Duopan Litong。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：辰欣药业股份有限公司Chinese legal name: 辰欣药业股份有限公司。
您可以探索含有相同成分的其他药品：多潘立酮-12f030aa成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 多潘立酮片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 多潘立酮Duopan Litong.
Manufacturers recorded for this product: 辰欣药业股份有限公司Chinese legal name: 辰欣药业股份有限公司.
Explore other medicines containing the same ingredient: 多潘立酮 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 多潘立酮片Recorded Chinese name: 多潘立酮片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 10mg*40片10 mg × 40 tablets
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 辰欣药业股份有限公司Chinese legal name: 辰欣药业股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20093791
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20093791
Manufacturer
Chinese legal name: 辰欣药业股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
10 mg × 40 tablets
中文说明书原文Original Chinese source label
批准文号
国药准字H20093791
生产企业
辰欣药业股份有限公司(国产)
适应症
用于消化不良、腹胀、嗳气、恶心、呕吐、腹部胀痛。
用法用量
本品口服。成人一次1片，一日3次，饭前15～30分钟服用。
不良反应
1.偶见轻度腹部痉挛、口干、皮疹、头痛、腹泻、神经过敏、倦耽嗜睡、头晕等。
2.有时导致血清泌乳素水平升高、溢乳、男子乳房女性化等，但停药后即可恢复正常。
禁忌
嗜铬细胞瘤、乳癌、机械性肠梗阻、胃肠出血等疾病患者禁用。
注意事项
1.孕妇慎用，哺乳期妇女使用本品期间应停止哺乳。
2.建议儿童使用多潘立酮混悬液。
3.心脏病患者（心律失常）以及接受化疗的肿瘤患者应用时需慎重，有可能加重心律紊乱。
4.如服用过量或出现严重不良反应，应立即就医。
5.对本品过敏者禁用，过敏体质者慎用。
6.本品性状发生改变时禁止使用。
7.请将本品放在儿童不能接触的地方。
8.如正在使用其他药品，使用本品前请咨询医师或药师。
贮藏
遮光，密封保存。
规格
10mg*40片
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.